Equities analysts expect that Immune Design Corp (NASDAQ:IMDZ) will announce sales of $810,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Immune Design’s earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $1.22 million. Immune Design posted sales of $2.06 million during the same quarter last year, which would indicate a negative year over year growth rate of 60.7%. The business is scheduled to issue its next earnings report after the market closes on Wednesday, March 14th.
According to Zacks, analysts expect that Immune Design will report full-year sales of $810,000.00 for the current fiscal year, with estimates ranging from $7.10 million to $9.00 million. For the next financial year, analysts forecast that the firm will post sales of $16.37 million per share, with estimates ranging from $14.73 million to $18.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Immune Design.
Several research firms have recently commented on IMDZ. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. Cowen reissued a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.13.
A number of hedge funds have recently added to or reduced their stakes in the business. Anson Funds Management LP acquired a new stake in Immune Design during the fourth quarter worth approximately $313,000. TIAA CREF Investment Management LLC raised its holdings in Immune Design by 49.0% during the fourth quarter. TIAA CREF Investment Management LLC now owns 63,192 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 20,777 shares in the last quarter. Teachers Advisors LLC raised its holdings in Immune Design by 71.4% during the fourth quarter. Teachers Advisors LLC now owns 56,367 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 23,475 shares in the last quarter. Bain Capital Public Equity Management LLC raised its holdings in Immune Design by 155.3% during the fourth quarter. Bain Capital Public Equity Management LLC now owns 3,316,769 shares of the biotechnology company’s stock worth $12,935,000 after purchasing an additional 2,017,756 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in Immune Design by 82.3% during the fourth quarter. California State Teachers Retirement System now owns 50,518 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 22,799 shares in the last quarter. 53.86% of the stock is currently owned by institutional investors.
Immune Design (IMDZ) opened at $3.95 on Wednesday. Immune Design has a 12 month low of $2.80 and a 12 month high of $13.05. The company has a market cap of $213.05, a P/E ratio of -1.85 and a beta of 2.09.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/810000-00-in-sales-expected-for-immune-design-corp-imdz-this-quarter.html.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.